Literature DB >> 25359084

The role of extracellular matrix quality in pulmonary fibrosis.

Jacob Hull Kristensen1, Morten Asser Karsdal, Federica Genovese, Simon Johnson, Birte Svensson, Susanne Jacobsen, Per Hägglund, Diana Julie Leeming.   

Abstract

This review discusses the role of extracellular matrix (ECM) quality in the pathogenesis of pulmonary fibrosis (PF). In PF, the highly ordered structure of collagens and elastin within the ECM of the lung is severely disrupted and lacks its original tissue quality. Discussions about the ECM have focused on the role of protein quantity in relation to the progression of PF, while the importance of lung ECM quality, defined by the levels of ECM protein modifications and by the protein distribution in lung tissue, has not been properly addressed. The quality and function of proteins may be altered by different post-translational modifications (PTMs), such as cross-linking, proteolytic cleavage, citrullination, misfolding and glycosylation. This paper is the first to review key data from the literature related to the lung ECM at the molecular level, relate these to changes observed at a macroscopic level and evaluate which PTMs most likely contribute to PF. This paper also reviews the role of novel neo-epitope-specific biomarkers in the early diagnosis and prognosis of fibrotic disorders. We discuss and argue that the altered quality of the individual ECM proteins contributes to the progression of PF and may also lead to the increased quantity of lung proteins. Thus, both quantity and quality appear to be of utmost importance.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359084     DOI: 10.1159/000368163

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  11 in total

1.  AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.

Authors:  Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  Transforming growth factor β1 alters the 3'-UTR of mRNA to promote lung fibrosis.

Authors:  Junsuk Ko; Tingting Mills; Jingjing Huang; Ning-Yuan Chen; Tinne C J Mertens; Scott D Collum; Garam Lee; Yu Xiang; Leng Han; Yang Zhou; Chun Geun Lee; Jack A Elias; Soma S K Jyothula; Keshava Rajagopal; Harry Karmouty-Quintana; Michael R Blackburn
Journal:  J Biol Chem       Date:  2019-09-05       Impact factor: 5.157

3.  Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling.

Authors:  Jacob H Kristensen; Morten A Karsdal; Jannie Mb Sand; Nicholas Willumsen; Claudia Diefenbach; Birte Svensson; Per Hägglund; Diana J Oersnes-Leeming
Journal:  BMC Pulm Med       Date:  2015-05-03       Impact factor: 3.317

4.  Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.

Authors:  Asger Reinstrup Bihlet; Morten Asser Karsdal; Jannie Marie Bülow Sand; Diana Julie Leeming; Mustimbo Roberts; Wendy White; Russell Bowler
Journal:  Respir Res       Date:  2017-01-19

5.  Long-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the lungs and pulmonary fibrosis via the nuclear factor-kappa B pathway.

Authors:  Yue Qin; Suning Li; Gan Zhao; Xuanhao Fu; Xueping Xie; Yiyi Huang; Xiaojing Cheng; Jinbin Wei; Huagang Liu; Zefeng Lai
Journal:  Int J Nanomedicine       Date:  2016-12-30

6.  A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis.

Authors:  D J Leeming; N Willumsen; J M B Sand; S Holm Nielsen; B Dasgupta; C Brodmerkel; M Curran; C L Bager; M A Karsdal
Journal:  Biochem Biophys Rep       Date:  2018-11-30

Review 7.  Macrophage-stroma interactions in fibrosis: biochemical, biophysical, and cellular perspectives.

Authors:  Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert
Journal:  J Pathol       Date:  2021-03-03       Impact factor: 7.996

Review 8.  Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Authors:  Nicholas Willumsen; Christina Jensen; George Green; Neel I Nissen; Jaclyn Neely; David M Nelson; Rasmus S Pedersen; Peder Frederiksen; Inna M Chen; Mogens K Boisen; Astrid Z Johansen; Daniel H Madsen; Inge Marie Svane; Allan Lipton; Kim Leitzel; Suhail M Ali; Janine T Erler; Daan P Hurkmans; Ron H J Mathijssen; Joachim Aerts; Mohammed Eslam; Jacob George; Claus Christiansen; Mina J Bissel; Morten A Karsdal
Journal:  Cell Mol Life Sci       Date:  2022-03-25       Impact factor: 9.207

9.  Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial.

Authors:  Toby M Maher; Susanne Stowasser; Yasuhiko Nishioka; Eric S White; Vincent Cottin; Imre Noth; Moisés Selman; Zuzana Blahova; Daniel Wachtlin; Claudia Diefenbach; R Gisli Jenkins
Journal:  BMJ Open Respir Res       Date:  2018-08-20

10.  Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts.

Authors:  Henrique Bregolin Dias; Jarbas Rodrigues de Oliveira; Márcio Vinícius Fagundes Donadio; Shioko Kimura
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.